ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Increased number of chemotherapy cycles during radiochemotherapy improves overall survival without increasing toxicity in locally advanced non-small cell lung cancer patients.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRadiochemotherapy (RCHT) followed by immunotherapy is the standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) patients. However, the impact of chemotherapy cycles and consolidation durvalumab on overall survival and toxicity remains uncertain in a real-life cohort.
methodsWe retrospectively analyzed 90 patients with stage IIB-IIIC LA-NSCLC treated with definitive RCHT (56-66 Gy, using weekly carboplatin/paclitaxel). Fifty of these patients received consolidation durvalumab. Chemotherapy cycles were analyzed as a stratified variable (1-4 vs. 5-7 cycles) and as a continuous predictor. Patients were also stratified by durvalumab administration. Early and late toxicities grade ≥ 2 were evaluated according to CTCAE v5.0. Overall survival (OS) was assessed via Kaplan-Meier analysis, log-rank test, Cox regression.
resultsMedian follow-up was 33.5 months. Patients receiving 5-7 chemotherapy cycles had significantly longer OS than those with 1-4 cycles (p = 0.048). This finding was confirmed when treating the cycle number as a continuous variable (HR = 0.75 per additional cycle; p = 0.017). Durvalumab showed a trend towards improved OS (p = 0.075). No significant increase in early or late toxicity was observed with more chemotherapy cycles. Amongst the toxicity parameters, early grade ≥ 2 anemia (27.8%) was associated with worse OS (p = 0.006).
conclusionReceipt of 5-7 chemotherapy cycles during RCHT was associated with improved OS without an increase in grade ≥ 2 toxicity. Early anemia emerged as a key prognostic marker and was closely linked to chemotherapy de-escalation. In addition, OS estimates in durvalumab-treated patients were broadly consistent with outcomes reported in pivotal post-CRT immunotherapy trials.
Indexed as
Identifiers
42850392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.